Terri Wrin

发表

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method

Mark C. Evans, Pham Phung, Agnes C. Paquet, 2014, BMC Bioinformatics.

Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus

Christos J. Petropoulos, Terri Wrin, Lidia Ruiz, 2006, The Journal of experimental medicine.

Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies

Renate Kunert, Bette Korber, Christos J. Petropoulos, 2004, Journal of Virology.

Rapid Escape from Preserved Cross-Reactive Neutralizing Humoral Immunity without Loss of Viral Fitness in HIV-1-Infected Progressors and Long-Term Nonprogressors

Terri Wrin, Becky Schweighardt, Hanneke Schuitemaker, 2010, Journal of Virology.

Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism

Christos J. Petropoulos, Terri Wrin, Wei Huang, 2006, Antimicrobial Agents and Chemotherapy.

Broad neutralization coverage of HIV by multiple highly potent antibodies

Pham Phung, Terri Wrin, Chi-Huey Wong, 2011, Nature.

Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Variation and Neutralizing Antibody Responses during Transmission of HIV-1 Subtype B

Yang Liu, Terri Wrin, Colombe Chappey, 2005, Journal of Virology.

HIV‐1 viral fitness estimation using exchangeable on subsets priors and prior model selection

Terri Wrin, Robert E Weiss, T. Wrin, 2007, Statistics in medicine.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Terri Wrin, E. Rosenberg, F. Pereyra, 2008, The Journal of infectious diseases.

A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1

Christos J. Petropoulos, Terri Wrin, Jeannette M. Whitcomb, 2000, Antimicrobial Agents and Chemotherapy.

The prevalence of antiretroviral drug resistance in the United States

Terri Wrin, Sally C Morton, Sandra Berry, 2004, AIDS.

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort

Ben Murrell, Jianming Tang, Adam Godzik, 2016, PLoS pathogens.

Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1

Christos J. Petropoulos, Terri Wrin, Simon D. W. Frost, 2005, Journal of Virology.

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Ben Murrell, Terri Wrin, Sergei L. Kosakovsky Pond, 2016, Immunity.

Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses

Christos J. Petropoulos, Terri Wrin, Steven G. Deeks, 2006, Journal of Virology.

Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies

Terri Wrin, Becky Schweighardt, W. Scott, 2009, Journal of Virology.

Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

Christoph Grundner, Christos J. Petropoulos, Terri Wrin, 2003, Journal of Virology.

Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies

Pham Phung, Terri Wrin, Becky Schweighardt, 2012, Journal of Virology.

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.

Kent J Weinhold, Terri Wrin, Guido Ferrari, 2003, The Journal of infectious diseases.

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.

Yang Liu, Terri Wrin, Sergei L. Kosakovsky Pond, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response

Terri Wrin, Rebecca Hoh, Robert M Grant, 2003, AIDS.

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Pham Phung, Terri Wrin, Dennis R. Burton, 2009, Science.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage

Ben Murrell, Terri Wrin, Sergei L. Kosakovsky Pond, 2017, Immunity.

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

Terri Wrin, Josephine Birungi, Dennis R. Burton, 2009, Journal of Virology.

PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4

Tongqing Zhou, Terri Wrin, Peter D. Kwong, 2012, Journal of Virology.